Abstract
Objective
Docetaxel given orally as monotherapy results in low bioavailability of <10%. Previous studies have indicated that the intestinal efflux pump P-glycoprotein (P-gp) prevents uptake from the gut resulting in low systemic exposure to docetaxel. The purpose of this study was to determine the degree of enhancement of the oral uptake of docetaxel on combination with orally administered OC144-093, a potent P-gp inhibitor. Furthermore, the safety of combined treatment was determined and whether known functional genetic polymorphisms of the MDR1 gene could be associated with variability in docetaxel pharmacokinetics was also investigated.
Patients and methods
A proof of concept study was carried out in 12 patients with advanced solid tumors. Patients were randomized to receive one course of 100 mg oral docetaxel combined with 500 mg OC144-093 followed 2 weeks later by a second i.v. course of docetaxel at a flat dose of 100 mg, without OC144-093, or vice versa. This was followed by standard i.v. docetaxel treatment if indicated.
Results
The apparent relative oral bioavailability of docetaxel was 26±8%. Orally administered docetaxel combined with oral OC144-093 resulted in a Cmax of 415±255 ng ml−1, an AUC0–∞ of 844±753 ng h ml−1 and kel of 0.810±0.296 h−1. These values differed significantly from those following i.v. administration of docetaxel, with a Cmax of 2124±1054 ng ml−1, an AUC0–∞ of 2571±1598 ng h ml−1 and a kel of 1.318±0.785 h−1 (P=0.003, P=0.006, P=0.016). The study medication was well tolerated and most of the adverse events possibly or probably related to OC144-093 and docetaxel were of CTC grade 1 and 2. One patient had a homozygous 3435T/T mutation, which is associated with low intestinal P-gp expression, and two other patients had a homozygous mutation on exon 21.
Conclusion
The relative apparent bioavailability of 26% was most likely caused by a significant effect of OC144-093 on the oral uptake of docetaxel. Large intrapatient and interpatient (pharmacokinetic) variation was found after oral as well as after i.v. administration of docetaxel. Higher plasma levels were observed after 100 mg i.v. docetaxel than after 100 mg oral docetaxel plus 500 mg oral OC144-093. The safety of the oral combination was good. More patients should be evaluated to determine the effect of P-gp single nucleotide polymorphisms on oral pharmacokinetic values of docetaxel.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JHM, Beijnen JH, van Tellingen O (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62:6158
Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, Noordaa J (1990) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495
Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbau M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169
Climent MA, Ruiz A, Llombart-Cussac A, Fernandez-Martos C, Poveda A, Dorta J, Guillem V (1999) Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results. Proc Am Soc Clin Oncol 18:119a
DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557
Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526
Frasci G, Comella P, D’Aiuto G, Thomas R, Capnoso I, Elmo M, Botti G, Cortino GR, Lapental L, DeRosa V, Vallone P, Petrillo A, Comella G (2000) Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 11:367
Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I (2002) MDR genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 54:610
Goh B-C, Lee S-C, Wang L-Z, Fan L, Guo J-Y, Lamba J, Schuetz E, Lim R, Lim H-L, Ong A-B, Lee H-S (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683
Division of Cancer Treatment (1998) Guidelines for reporting of adverse drug reactions. National Cancer Institute, Bethesda, MD
Guns ES, Bullock PL, Reimer ML, Dixon R, Bally M, Mayer LD (2001) Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-093, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26:273
Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M (2003) Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 97:412
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlations of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473
Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinge R, Dreissler H (2003) Polymorphisms C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22:1117
Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189
Koukourakis MI, Bahlitzanakis N, Froudarakis M, Giatromanolaki A, Georgoulias V, Koumiotaki S, Christodoulou M, Kyrias G, Skarlatos J, Kostantelos J, Beroukas J (1999) Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer 80:1792
Kruijtzer CMF, Malingré MM, Schornagel JH, Smit WM, Richel DJ, ten Bokkel Huinink WW, Rosing H, de Gast GC, Schot M, Mackay M, Beijnen JH, Schellens JHM (2002) Activity and toxicity of weekly oral docetaxel plus cyclosporin A in patients with metastatic breast cancer. Results of a phase II study. Thesis University Utrecht Clinical evaluation of novel strategies for oral chemotherapy
Liu G, Franssen E, Fitch MI, Warner E (1997) Patients preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110
Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, ten Bokkel Huinink WW, Schot ME, Schellens JHM (2001) Coadministration of cyclosporine strongly enhanced the oral bioavailability of docetaxel. J Clin Oncol 19:1160
Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD (2000) Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60:2964
Rosing H, Lustig V, Koopman FJ, ten Bokkel Huinink WW, Beijnen JH (1997) Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J Chromatogr B 696:89
Rosing H, Lustig V, Van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, Schellens JH, Rodenhuis S, Bult A, Beijnen JH (2000) Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 45:213
Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga MK, Okumura K (2001) MDR genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400
Schellens JH, Malingré MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH, Beijnen JH (2000) Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 12:103
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willlingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735
Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10:159
Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528
Acknowledgements
This work was supported by Elan Pharmaceutical Technologies (Athlone, Ireland) through their joint venture with Avmax, Inc. (So. San Francisco, Calif.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuppens, I.E.L.M., Bosch, T.M., van Maanen, M.J. et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 55, 72–78 (2005). https://doi.org/10.1007/s00280-004-0864-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-004-0864-4